Clinical Trial Data Transparency in Canada: Mapping the Progress From Laggard to Leader

Matthew Herder, Marc-André Gagnon, Janice Graham, Katherine Fierlbeck, Anna Danyliuk

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that the pharmaceutical industry is both socially beneficial and profitable. Regulators are expected to ensure that the economic success of the industry does not come at the expense of public safety, yet they have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between the pharmaceutical industry and government regulators.

    Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.

    Original languageCanadian English
    Title of host publicationClinical Trial Data Transparency in Canada: Mapping the Progress From Laggard to Leader
    Publication statusPublished - Jan. 1 2021

    Keywords

    • Clinical Research
    • Big Data
    • Clinical Trials
    • Canada

    Disciplines

    • Food and Drug Law
    • Health Law and Policy
    • Law
    • Medical Jurisprudence
    • Science and Technology Law

    Fingerprint

    Dive into the research topics of 'Clinical Trial Data Transparency in Canada: Mapping the Progress From Laggard to Leader'. Together they form a unique fingerprint.

    Cite this